Association between Hemoglobin and Diabetic Peripheral Neuropathy at Different Glycosylated Hemoglobin Levels in Type 2 Diabetes Mellitus Patients

Abstract Background: To investigate the possible association of diabetic peripheral neuropathy (DPN) and serum hemoglobin levels in type 2 diabetes mellitus (T2DM) patients with different glycosylated hemoglobin levels.Methods: A total of 995 patients were involved in this retrospective cross-sectional study. Laboratory medical data and electromyography results from the patients were collected. The patients were divided into five groups according to their HbA1c levels (Group 1: HbA1c ≤7%, Group 2: HbA1c 7% to ≤8%, Group 3: HbA1c 8% to ≤9%, Group 4: 9% to ≤10%, and Group 5: >10%). Differences in clinical data in the five groups were compared. Analysis of variance (ANOVA) and binary logistic regression analysis were used. All analyses were performed using SPSS 24 (SPSS Inc., Chicago, IL, USA). P value < 0.05 was considered to indicate statistical significance.Results: A correlation was found between the prevalence of DPN and anemia in both sex groups. Age, BMI, duration of diabetes, ALT, serum creatinine, TC, TG, LDL, FPG, FCP, and hemoglobin A1c differed to a statistically significant extent in different groups. Group 5 showed the highest prevalence of DPN in both sex groups. Hemoglobin levels were higher in Group 5 than in other groups, while composition of anemia was not statistically different. Binary logistic regression showed hemoglobin to be negatively related to the prevalence of DPN in Group 5 in men and in Group 4 in women.Conclusion: Hemoglobin level was negatively associated with the occurrence of DPN at the HbA1c level of >10% in men and 9 to 10% in women in T2DM patients. HbA1c must be considered in exploring the correlation between hemoglobin and DPN.

Download Full-text

Association between Hemoglobin and Diabetic Peripheral Neuropathy at Different Glycosylated Hemoglobin Levels in Type 2 Diabetes Mellitus Patients

10.21203/rs.3.rs-16650/v1 ◽

2020 ◽

Author(s):

Lingling Zhou ◽

Xiaojuan Xu ◽

Hui Sheng ◽

Shen Qu ◽

Ran Cui

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Logistic Regression ◽

Peripheral Neuropathy ◽

Glycosylated Hemoglobin ◽

Binary Logistic Regression ◽

Group 4 ◽

Group 5

Abstract Background To investigate the possible association of diabetic peripheral neuropathy (DPN) and serum hemoglobin levels in type 2 diabetes mellitus (T2DM) patients with different glycosylated hemoglobin levels. Methods A total of 995 patients were involved in this retrospective cross-sectional study. Laboratory medical data and electromyography results from the patients were collected. The patients were divided into five groups according to their HbA1c levels (Group 1: HbA1c ≤7%, Group 2: HbA1c 7% to ≤8%, Group 3: HbA1c 8% to ≤9%, Group 4: 9% to ≤10%, and Group 5: >10%). Differences in clinical data in the five groups were compared. Analysis of variance (ANOVA) and binary logistic regression analysis were used. All analyses were performed using SPSS 24 (SPSS Inc., Chicago, IL, USA). P value < 0.05 was considered to indicate statistical significance. Results A correlation was found between the prevalence of DPN and anemia in both sex groups. Age, BMI, duration of diabetes, ALT, serum creatinine, TC, TG, LDL, FPG, FCP, and hemoglobin A1c differed to a statistically significant extent in different groups. Group 5 showed the highest prevalence of DPN in both sex groups. Hemoglobin levels were higher in Group 5 than in other groups, while composition of anemia was not statistically different. Binary logistic regression showed hemoglobin to be negatively related to the prevalence of DPN in Group 5 in men and in Group 4 in women. Conclusion Hemoglobin level was negatively associated with the occurrence of DPN at the HbA1c level of >10% in men and 9 to 10% in women in T2DM patients. HbA1c must be considered in exploring the correlation between hemoglobin and DPN.

Download Full-text

Binary logistic regression analysis of the association between body mass index and glycemic control in patients with type 2 diabetes mellitus: a teaching-case study

Pan African Medical Journal ◽

10.11604/pamj.supp.2019.33.1.18686 ◽

2019 ◽

Vol 33 ◽

Author(s):

Yousef Khader

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Body Mass Index ◽

Type 2 Diabetes Mellitus ◽

Logistic Regression ◽

Regression Analysis ◽

Binary Logistic Regression ◽

Binary Logistic Regression Analysis

Download Full-text

Novel binary logistic regression model based on feature transformation of XGBoost for type 2 Diabetes Mellitus prediction in healthcare systems

Future Generation Computer Systems ◽

10.1016/j.future.2021.11.003 ◽

2021 ◽

Author(s):

Yalin Wu ◽

Qianjian Zhang ◽

Yaqin Hu ◽

Ko Sun-Woo ◽

Xiangyan Zhang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Logistic Regression ◽

Logistic Regression Model ◽

Binary Logistic Regression ◽

Healthcare Systems ◽

Feature Transformation ◽

Binary Logistic Regression Model

Download Full-text

High HBA1C Level Is Associated With Low Heamoglobin Level

International Journal of Innovative Research in Medical Science ◽

10.23958/ijirms/vol03-i02/15 ◽

2018 ◽

Vol 3 (02) ◽

Author(s):

Mafooza Rashid ◽

B. K. Gupta, Vinay Bharat ◽

Abhishek Gupta ◽

Zubair Rashid

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycosylated Hemoglobin ◽

Good Control ◽

Diabetic Control ◽

Medical College ◽

High Hba1c ◽

Normal Controls

Background: The aim of the study was to compare the hemoglobin levels among normal controls (patients) and patients of TypeII diabetes with HbA1c levels below 7 % & above 7 %.and secondly to identify the undetected cases of anemia in TypeII diabetes. Materials & Methods - 50 patients of type 2 diabetes mellitus with their glycosylated hemoglobin levels less than 7 %, 50 patients of type 2 diabetes mellitus with their glycosylated hemoglobin levels more than 7 % attending the Medicine outpatient department of Subharti Medical College and Hospital will be the subjects for the study.50 age and sex matched controls will be selected randomly from Subharti Medical College and Hospital. Informed written consent will be taken from all the subjects. The study will be conducted from January 2016 to January. Result - We studied 50 cases with HbA1C>7(poor control),50 cases with HbA1C 5.6 to7 (good control) and 50 controls with HbA1C ≤5.6, we observed in cases with HbA1C>7 (poorly control) ,the mean HbA1C is 9.9±2 and mean Hb is 9.8±1.3 as compared to cases with HbA1C 5.6 to 7(good control) where mean HbA1C is 6±0.4 and Hb is 13±0.5,this clearly indicates that in cases HbA1C is more Hb levels are low and when HbA1C is less Hb levels are higher. Conclusion - In the present study we found negative correlation between HbA1c & Hb levels. As the value of HbA1c increases, as in cases of HbA1c >7(poor diabetic control), we found low Hb levels as compared to the cases with HbA1c <7(5.6-7) (good control).

Download Full-text

Which Occurs First in Patients with Type 2 Diabetes Mellitus? Central or Peripheral Neuropathy

International Archives of BioMedical and Clinical Research ◽

10.21276/iabcr.2016.2.2.16 ◽

2016 ◽

Vol 2 (2) ◽

Author(s):

Raju Panta ◽

Dr. Rita Khadka ◽

Dilip Thakur ◽

Nirmala Limbu ◽

Bishnu Hari Paudel

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Peripheral Neuropathy

Download Full-text

Incretin-Based Therapies in Type 2 Diabetes Mellitus

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2007-2109 ◽

2008 ◽

Vol 93 (10) ◽

pp. 3703-3716 ◽

Cited By ~ 137

Author(s):

Chee W. Chia ◽

Josephine M. Egan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Weight Loss ◽

Type 2 Diabetes Mellitus ◽

Evidence Synthesis ◽

Glycosylated Hemoglobin ◽

Cell Mass ◽

New Drugs ◽

Medline Search

Context: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide are incretins secreted from enteroendocrine cells postprandially in part to regulate glucose homeostasis. Dysregulation of these hormones is evident in type 2 diabetes mellitus (T2DM). Two new drugs, exenatide (GLP-1 mimetic) and sitagliptin [dipeptidyl peptidase (DPP) 4 inhibitor], have been approved by regulatory agencies for treating T2DM. Liraglutide (GLP-1 mimetic) and vildagliptin (DPP 4 inhibitor) are expected to arrive on the market soon. Evidence Acquisition: The background of incretin-based therapy and selected clinical trials of these four drugs are reviewed. A MEDLINE search was conducted for published articles using the key words incretin, glucose-dependent insulinotropic polypeptide, GLP-1, exendin-4, exenatide, DPP 4, liraglutide, sitagliptin, and vildagliptin. Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year follow-up data on exenatide showed a sustained weight loss and glycosylated hemoglobin (HbA1c) reduction of 1%. Nausea and vomiting are common. Results from phase 3 studies are pending on liraglutide. Sitagliptin and vildagliptin are orally active. In 24-wk studies, sitagliptin reduces HbA1c by 0.6–0.8% as monotherapy, 1.8% as initial combination therapy with metformin, and 0.7% as add-on therapy to metformin. Vildagliptin monotherapy lowered HbA1c by 1.0–1.4% after 24 wk. Their major side effects are urinary tract and nasopharyngeal infections and headaches. Exenatide and liraglutide cause weight loss, whereas sitagliptin and vildagliptin do not. Conclusions: The availability of GLP-1 mimetics and DPP 4 inhibitors has increased our armamentarium for treating T2DM. Unresolved issues such as the effects of GLP-1 mimetics and DPP 4 inhibitors on β-cell mass, the mechanism by which GLP-1 mimetics lowers glucagon levels, and exactly how DPP 4 inhibitors lead to a decline in plasma glucose levels without an increase in insulin secretion, need further research.

Download Full-text